Cargando…
Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
[Image: see text] While screening off-target effects of rigid (N)-methanocarba-adenosine 5′-methylamides as A(3) adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). In an effort to increase OR and decrease AR affinity by str...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210068/ https://www.ncbi.nlm.nih.gov/pubmed/30411015 http://dx.doi.org/10.1021/acsomega.8b01237 |
_version_ | 1783367033512001536 |
---|---|
author | Tosh, Dilip K. Ciancetta, Antonella Mannes, Philip Warnick, Eugene Janowsky, Aaron Eshleman, Amy J. Gizewski, Elizabeth Brust, Tarsis F. Bohn, Laura M. Auchampach, John A. Gao, Zhan-Guo Jacobson, Kenneth A. |
author_facet | Tosh, Dilip K. Ciancetta, Antonella Mannes, Philip Warnick, Eugene Janowsky, Aaron Eshleman, Amy J. Gizewski, Elizabeth Brust, Tarsis F. Bohn, Laura M. Auchampach, John A. Gao, Zhan-Guo Jacobson, Kenneth A. |
author_sort | Tosh, Dilip K. |
collection | PubMed |
description | [Image: see text] While screening off-target effects of rigid (N)-methanocarba-adenosine 5′-methylamides as A(3) adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). In an effort to increase OR and decrease AR affinity by structure activity analysis of this series, antagonist activity at κ-(K)OR appeared in 5′-esters (ethyl 24 and propyl 30), which retained TSPO interaction (μM). 7-Deaza modification of C2-(arylethynyl)-5′-esters but not 4′-truncation enhanced KOR affinity (MRS7299 28 and 29, K(i) ≈ 40 nM), revealed μ-OR and DOR binding, and reduced AR affinity. Molecular docking and dynamics simulations located a putative KOR binding mode consistent with the observed affinities, placing C7 in a hydrophobic region. 3-Deaza modification permitted TSPO but not OR binding, and 1-deaza was permissive to both; ribose-restored analogues were inactive at both. Thus, we have repurposed a known AR nucleoside scaffold for OR antagonism, with a detailed hypothesis for KOR recognition. |
format | Online Article Text |
id | pubmed-6210068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-62100682018-11-06 Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists Tosh, Dilip K. Ciancetta, Antonella Mannes, Philip Warnick, Eugene Janowsky, Aaron Eshleman, Amy J. Gizewski, Elizabeth Brust, Tarsis F. Bohn, Laura M. Auchampach, John A. Gao, Zhan-Guo Jacobson, Kenneth A. ACS Omega [Image: see text] While screening off-target effects of rigid (N)-methanocarba-adenosine 5′-methylamides as A(3) adenosine receptor (AR) agonists, we discovered μM binding hits at the δ-opioid receptor (DOR) and translocator protein (TSPO). In an effort to increase OR and decrease AR affinity by structure activity analysis of this series, antagonist activity at κ-(K)OR appeared in 5′-esters (ethyl 24 and propyl 30), which retained TSPO interaction (μM). 7-Deaza modification of C2-(arylethynyl)-5′-esters but not 4′-truncation enhanced KOR affinity (MRS7299 28 and 29, K(i) ≈ 40 nM), revealed μ-OR and DOR binding, and reduced AR affinity. Molecular docking and dynamics simulations located a putative KOR binding mode consistent with the observed affinities, placing C7 in a hydrophobic region. 3-Deaza modification permitted TSPO but not OR binding, and 1-deaza was permissive to both; ribose-restored analogues were inactive at both. Thus, we have repurposed a known AR nucleoside scaffold for OR antagonism, with a detailed hypothesis for KOR recognition. American Chemical Society 2018-10-04 /pmc/articles/PMC6210068/ /pubmed/30411015 http://dx.doi.org/10.1021/acsomega.8b01237 Text en Copyright © 2018 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Tosh, Dilip K. Ciancetta, Antonella Mannes, Philip Warnick, Eugene Janowsky, Aaron Eshleman, Amy J. Gizewski, Elizabeth Brust, Tarsis F. Bohn, Laura M. Auchampach, John A. Gao, Zhan-Guo Jacobson, Kenneth A. Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists |
title | Repurposing of a Nucleoside Scaffold from Adenosine
Receptor Agonists to Opioid Receptor Antagonists |
title_full | Repurposing of a Nucleoside Scaffold from Adenosine
Receptor Agonists to Opioid Receptor Antagonists |
title_fullStr | Repurposing of a Nucleoside Scaffold from Adenosine
Receptor Agonists to Opioid Receptor Antagonists |
title_full_unstemmed | Repurposing of a Nucleoside Scaffold from Adenosine
Receptor Agonists to Opioid Receptor Antagonists |
title_short | Repurposing of a Nucleoside Scaffold from Adenosine
Receptor Agonists to Opioid Receptor Antagonists |
title_sort | repurposing of a nucleoside scaffold from adenosine
receptor agonists to opioid receptor antagonists |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210068/ https://www.ncbi.nlm.nih.gov/pubmed/30411015 http://dx.doi.org/10.1021/acsomega.8b01237 |
work_keys_str_mv | AT toshdilipk repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT ciancettaantonella repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT mannesphilip repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT warnickeugene repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT janowskyaaron repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT eshlemanamyj repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT gizewskielizabeth repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT brusttarsisf repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT bohnlauram repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT auchampachjohna repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT gaozhanguo repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists AT jacobsonkennetha repurposingofanucleosidescaffoldfromadenosinereceptoragoniststoopioidreceptorantagonists |